You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

Details for Patent: 10,208,089


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 10,208,089 protect, and when does it expire?

Patent 10,208,089 protects ZILBRYSQ and is included in one NDA.

This patent has eighty-six patent family members in twenty-eight countries.

Summary for Patent: 10,208,089
Title:Modulation of complement activity
Abstract:The present invention provides modulators of complement activity. Also provided are methods of utilizing such modulators as therapeutics.
Inventor(s):Hoarty Michelle Denise, Dhamnaskar Ketki Ashok, Elbaum Daniel, Josephson Kristopher, Larson Kelley Cronin, Ma Zhong, Nims Nathan Ezekiel, Ricardo Alonso, Seyb Kathleen, Tang Guo-Qing, Treco Douglas A., Wang Zhaolin, Ye Ping, Zheng Hong, Perlmutter Sarah Jacqueline, Hammer Robert Paul
Assignee:Ra Pharmaceuticals, Inc.
Application Number:US16128561
Patent Claim Types:
see list of patent claims
 

Drugs Protected by US Patent 10,208,089

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Ucb Inc ZILBRYSQ zilucoplan sodium SOLUTION;SUBCUTANEOUS 216834-001 Oct 17, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y TREATMENT OF GENERALIZED MYASTHENIA GRAVIS (GMG) IN AN ADULT PATIENT WHO IS ANTI-ACETYLCHOLINE RECEPTOR (ACHR) ANTIBODY POSITIVE BY SUBCUTANEOUS ADMINISTRATION OF C5 COMPLEMENT INHIBITOR ZILUCOPLAN ⤷  Sign Up
Ucb Inc ZILBRYSQ zilucoplan sodium SOLUTION;SUBCUTANEOUS 216834-002 Oct 17, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y TREATMENT OF GENERALIZED MYASTHENIA GRAVIS (GMG) IN AN ADULT PATIENT WHO IS ANTI-ACETYLCHOLINE RECEPTOR (ACHR) ANTIBODY POSITIVE BY SUBCUTANEOUS ADMINISTRATION OF C5 COMPLEMENT INHIBITOR ZILUCOPLAN ⤷  Sign Up
Ucb Inc ZILBRYSQ zilucoplan sodium SOLUTION;SUBCUTANEOUS 216834-003 Oct 17, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y TREATMENT OF GENERALIZED MYASTHENIA GRAVIS (GMG) IN AN ADULT PATIENT WHO IS ANTI-ACETYLCHOLINE RECEPTOR (ACHR) ANTIBODY POSITIVE BY SUBCUTANEOUS ADMINISTRATION OF C5 COMPLEMENT INHIBITOR ZILUCOPLAN ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,208,089

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 3154561 ⤷  Sign Up CA 2024 00021 Denmark ⤷  Sign Up
European Patent Office 3154561 ⤷  Sign Up 301275 Netherlands ⤷  Sign Up
European Patent Office 3154561 ⤷  Sign Up PA2024514 Lithuania ⤷  Sign Up
European Patent Office 3154561 ⤷  Sign Up LUC00343 Luxembourg ⤷  Sign Up
European Patent Office 3154561 ⤷  Sign Up 2024C/518 Belgium ⤷  Sign Up
European Patent Office 3154561 ⤷  Sign Up 17/2024 Austria ⤷  Sign Up
Australia 2015274482 ⤷  Sign Up
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.